Intelligence Platform

Patents

Browse 173 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10441645

MSLN targeting DNA vaccine for cancer immunotherapy

Vaximm AG · Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426797

Compositions and methods for treating cancer with anti-CD33 immunotherapy

United State of America, As Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420799

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10398734

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392439

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10363273

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10301365

Met e 1 tropomyosin variants for use in allergen-specific immunotherapy

The Regents of the University of California · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10272113

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10258678

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10166257

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10166277

Vault immunotherapy

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10167337

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130659

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130658

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a smal

Provectus Pharmatech, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10117915

Modulation of yeast-based immunotherapy products and responses

The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10036751

Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment

China Medical University Hospital · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023637

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9920297

Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1

Vaximm AG · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9920100

Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy

The Regents of the University of California · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9907820

Polyclonal gamma delta T cells for immunotherapy

The Board of Regents of the University of Texas System · Granted Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9855330

Granulysin in immunotherapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9433666

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS · Granted Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9399662

Concurrent chemotherapy and immunotherapy

The Board of Regents of the University of Texas System · Granted Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9375475

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted